Journal article
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Abstract
BACKGROUND: Diabetes mellitus is a strong risk factor for cardiovascular and renal disease. We investigated whether the angiotensin-converting-enzyme (ACE) inhibitor ramipril can lower these risks in patients with diabetes.
METHODS: 3577 people with diabetes included in the Heart Outcomes Prevention Evaluation study, aged 55 years or older, who had a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical …
Authors
Investigators HOPES
Journal
The Lancet, Vol. 355, No. 9200, pp. 253–259
Publisher
Elsevier
Publication Date
January 2000
DOI
10.1016/s0140-6736(99)12323-7
ISSN
0140-6736